[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,308,738
  • Shares Outstanding, K 100,550
  • Annual Sales, $ 2,861 M
  • Annual Income, $ 478,600 K
  • EBIT $ 619 M
  • EBITDA $ 637 M
  • 60-Month Beta 0.34
  • Price/Sales 5.26
  • Price/Cash Flow 29.84
  • Price/Book 4.41

Options Overview Details

View History
  • Implied Volatility 39.01% (+2.61%)
  • Historical Volatility 35.57%
  • IV Percentile 72%
  • IV Rank 57.57%
  • IV High 51.29% on 04/16/26
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 4) 8.88 (5.83%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 280
  • Volume Avg (30-Day) 303
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 13,111
  • Open Int (30-Day) 11,292
  • Expected Range 143.37 to 161.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.62
  • Number of Estimates 4
  • High Estimate $2.18
  • Low Estimate $1.36
  • Prior Year $1.06
  • Growth Rate Est. (year over year) +52.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.64 +21.18%
on 04/13/26
154.74 -1.61%
on 05/08/26
+19.10 (+14.34%)
since 04/08/26
3-Month
122.14 +24.65%
on 02/12/26
154.74 -1.61%
on 05/08/26
+11.05 (+7.83%)
since 02/06/26
52-Week
115.66 +31.64%
on 05/09/25
160.18 -4.95%
on 12/08/25
+34.73 (+29.55%)
since 05/08/25

Most Recent Stories

More News
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

SAN DIEGO , May 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose...

NBIX : 152.25 (+1.78%)
Neurocrine: Q1 Earnings Snapshot

Neurocrine: Q1 Earnings Snapshot

NBIX : 152.25 (+1.78%)
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year

NBIX : 152.25 (+1.78%)
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

SAN DIEGO , May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20...

NBIX : 152.25 (+1.78%)
Can Neurocrine Biosciences Justify Its Valuation Without Pipeline Surprises?

Barchart Research What to Expect from NBIX Earnings NBIX Generated May 4, 2026 Current Price $134.07 EPS Estimate $$1.28 Consensus Rating Strong Buy Average Move 6.93% Can Neurocrine Biosciences Justify...

NBIX : 152.25 (+1.78%)
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

SAN DIEGO , May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive...

NBIX : 152.25 (+1.78%)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

SAN DIEGO , May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability...

NBIX : 152.25 (+1.78%)
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

SAN DIEGO , May 1, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the presentation of new two-year data from the Phase 3 CAHtalyst ® Pediatric study...

NBIX : 152.25 (+1.78%)
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

SAN DIEGO , April 29, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry...

NBIX : 152.25 (+1.78%)
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia

SAN DIEGO , April 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst ® Adult study...

NBIX : 152.25 (+1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 160.01
2nd Resistance Point 157.38
1st Resistance Point 154.81
Last Price 152.25
1st Support Level 149.61
2nd Support Level 146.98
3rd Support Level 144.41

See More

52-Week High 160.18
Last Price 152.25
Fibonacci 61.8% 143.17
Fibonacci 50% 137.92
Fibonacci 38.2% 132.67
52-Week Low 115.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.